迈威生物(688062.SH)：9MW3811注射液临床试验申请获得国家药品监督管理局批准

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its drug 9MW3811, targeting pathological scars in a Phase II study [1] Company Summary - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, classified as a Class 1 therapeutic biological product with independent intellectual property rights [1] - The drug effectively inhibits the abnormal activation of the IL-11/IL-11Rα signaling pathway, which is crucial in the progression of fibrotic diseases [1] - Key advantages of 9MW3811 include higher target affinity and signaling blockade capability, along with a long half-life of over one month, making it suitable for chronic disease treatment requiring long-term administration [1]